
Why Is Small Cap Sol-Gel Tech Stock Falling Today?

I'm PortAI, I can summarize articles.
Sol-Gel Technologies (NASDAQ:SLGL) has halted the development of SGT-210 for Darier disease after Phase 1b trials showed no efficacy. The company will focus on small feasibility studies in other areas and prioritize its Phase 3 program for SGT-610 in Gorlin syndrome. Despite the stock's recent decline, technical analysis indicates a strong bullish trend, with key support at $34.50 and resistance at $43.50. SLGL has gained 735.02% over the past year, trading at 77.2% of its 52-week range.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

